Stem Cell Therapy for Scleroderma

What This Article Covers

For most people researching “stem cells for scleroderma,” the relevant procedure is not a same-day infusion at a wellness clinic — it's autologous hematopoietic stem cell transplantation (AHSCT), a demanding, hospital-based procedure with some of the strongest randomized-trial evidence in regenerative medicine for severe, rapidly progressing diffuse systemic sclerosis. This article covers how it works, what three major clinical trials found, who realistically qualifies, and why — despite genuinely encouraging survival data — it remains a high-risk therapy reserved for specialized centers rather than a routine or FDA-approved treatment.

How It's Thought to Work

Systemic sclerosis is driven by an immune system that has turned against the body's own connective tissue, triggering the fibrosis (scarring) of skin, lungs, heart, and other organs that defines the disease. AHSCT is built on a “reset” logic: doctors first collect a patient's own hematopoietic (blood-forming) stem cells from their bone marrow or bloodstream. The patient then receives high-dose chemotherapy — and in some protocols, radiation — intended to destroy the existing, dysfunctional immune system driving the autoimmune attack. Finally, the patient's own banked stem cells are reinfused, allowing a new immune system to regenerate, ideally without the same autoreactive tendencies.

This distinction matters: AHSCT is fundamentally different from the mesenchymal stem cell (MSC) infusions sometimes marketed directly to scleroderma patients by clinics. AHSCT is a multi-week inpatient transplant procedure with serious, well-documented risks, while MSC infusions for scleroderma are far less studied and not backed by the caliber of evidence below.

What the Evidence Shows

The case for AHSCT rests on three randomized controlled trials — a rarity in this field, and worth taking seriously. In the ASSIST trial (Burt et al., The Lancet, 2011), a small phase 2 study, AHSCT outperformed monthly cyclophosphamide, the prior standard of care, on lung function and skin thickening. The larger ASTIS trial (van Laar et al., JAMA, 2014), randomizing 156 patients with early diffuse disease, found AHSCT carried a higher risk of death in the first year — including treatment-related deaths absent in the cyclophosphamide group — but went on to show a clear long-term survival advantage, with the risk of death or major organ failure roughly two-thirds lower in the transplant group by four years.

That long-term benefit was confirmed and extended by the SCOT trial (Sullivan et al., New England Journal of Medicine, 2018), which followed 75 patients with severe scleroderma for up to six years. Transplant recipients had substantially better outcomes than those treated with cyclophosphamide, including markedly better event-free and overall survival and far less need for additional immunosuppressive drugs afterward, per the trial's published results and independent reporting on them. This is a genuinely rare finding in autoimmune disease research — a therapy showing an actual survival advantage in a head-to-head randomized trial, not just symptom improvement.

That benefit came with a real cost, though. Both major trials recorded treatment-related deaths in the transplant arm, along with serious toxicity, and SCOT investigators also observed cases of secondary myelodysplastic syndrome, a blood cancer risk linked to the conditioning chemotherapy. AHSCT is not a low-risk procedure, and these trials enrolled carefully selected, closely monitored patients at experienced transplant centers — not a general scleroderma population.

Who Might Be a Candidate

AHSCT is not appropriate for most people with scleroderma, including many with mild or limited disease. Based on criteria used in clinical trials and by insurers such as Aetna, candidates are typically:

• Adults with severe, rapidly progressive diffuse cutaneous systemic sclerosis, usually within the first several years of onset
• Patients with organ involvement — most often active interstitial lung disease with reduced lung function, or scleroderma-related kidney disease
• Free of major disqualifying organ damage, such as significant pulmonary hypertension, poor heart function, or advanced kidney impairment, which sharply raise transplant risk
• Generally younger patients with adequate cardiac, renal, and pulmonary reserve to tolerate conditioning chemotherapy
• Able to be treated at a specialized transplant center with rheumatology and hematology expertise, given the intensity of monitoring required

Bottom Line

AHSCT is one of the few regenerative therapies backed by multiple randomized controlled trials showing a real survival benefit — for patients facing severe, organ-threatening diffuse scleroderma, that is genuinely important news. But it is not an FDA-approved, standardized treatment; it is an intensive, off-label procedure offered as standard of care at a limited number of specialized transplant centers, carrying meaningful risks of treatment-related death, infection, and secondary cancers. It is best understood not as a cure or a routine option, but as a high-stakes, carefully gatekept therapy for a specific, high-risk subset of patients — one to discuss with a rheumatologist experienced in transplant referral, not to seek out independently.